Roth Capital assumed coverage on shares of Eyenovia (NASDAQ:EYEN) in a research report sent to investors on Tuesday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $20.00 price target on the stock.

Shares of Eyenovia (EYEN) opened at $9.55 on Tuesday. The stock has a market capitalization of $94.90 and a price-to-earnings ratio of -22.74. Eyenovia has a 1-year low of $7.32 and a 1-year high of $10.74.

In other Eyenovia news, Director Fredric N. Eshelman bought 335,000 shares of Eyenovia stock in a transaction dated Monday, January 29th. The stock was bought at an average price of $10.00 per share, for a total transaction of $3,350,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

TRADEMARK VIOLATION WARNING: “Eyenovia (EYEN) Earns Buy Rating from Analysts at Roth Capital” was originally reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at

Eyenovia Company Profile

Eyenovia, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing a pipeline of ophthalmology products utilizing its piezo-print technology to deliver micro-doses of active pharmaceutical ingredients (micro-therapeutics) to the eye. Its product candidates include MicroProst, MicroStat, MicroTears and MicroPine.

Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with's FREE daily email newsletter.